, cleaved caspase-3 ( Fig. 2, 4) complement C3a receptor, extracellular signal-regulated kinase (ERK), intracellular adhesion molecule-1 (ICAM-1) apoptosis Basuroy 2013 23576575 ischemic glutamate toxicity in primary pig CMVEC in vitro cytoplasmic DNA fragments detected by ELISA (Fig. 2, 7 , 10), floating cells (Fig. 3, 7) , Ca 2+ (Fig.  4) , cytochrome c ( Fig. 8) n/a apoptosis Butt 2011 21356382 hemorrhagic systemic application of cell-free hemoglobin in guinea pig in vivo cleaved caspase-3 ( Fig. 8 nuclear condensation with DAPI ( Fig. 2) , AnxA5/PI (Fig. 3) , cleaved caspase-3, BAX, BCL2 (Fig. 4) n/a apoptosis Cui 2016 26111628 hemorrhagic rat autologous blood SAH in vivo vWF+TUNEL in ACA and MCA ( Fig. 8 Calpain-1/2 activity (Fig. 2) , pJNK1/2 and cleaved caspase-3 ( Fig. 5 ) liver X receptor, ATP-binding cassette transporters (ABCG1) apoptosis Engelhar dt 2015 25879623 ischemic RBE4, primary rat brain EC in OD and OGD in vitro MTT (Fig. 5 ), BNIP3 (Fig. 6) , BAX, Beclin-1 ( Fig. 7) , LC3-II ( Fig. 8) n/a apoptosis Fang 2016 26887441 ischemic OGD in BMEC in vitro AnxA5/PI (Fig. 2, 6 MTT, Annexin A5/PI, cleaved caspase-3 ( Fig. 1 ), in vivo: only in whole brain/neurons ( Fig. 5-7 Trypan blue, TUNEL, Phosphatidylserine externalization ( Fig. 1, 4) , mitochondrial depolarization, cytochrome c release, BAD activation ( Fig. 7) , cleaved caspase-1/3 ( Fig. 8 WST-8/CCK-8 ( Fig. 2) , Hoechst 33342, TUNEL (Fig. 3) , cleaved caspase-3/7 ( Fig. 4) , mitochondrial membrane potential ( Fig. 5 Glut-1 + cells, mostly not TUNEL + ( 
cells in vitro
AnxA5/PI, cleaved caspase-3/9 ( Fig. 3) , pJNK, c-JUN ( Fig. 4 ), SP600125 -JNK inhibitor ( CCK-8 ( Fig. 1 ), Annexin A5/PI, BCL2, cleaved caspase-3, autophagosome (EM), mTOR, Beclin-1 ( Fig. 3 (Fig. 1, 2 , 4, 5), deferoxamine, trolox ( Fig. 1) , LDH, AnxA5 (Fig. 2) , cleaved caspase-3 ( Fig. 3, 4 Fig. 2 ), Hoechst nuclear staining (Fig. 4) , Annexin A5/7-AAD ( Fig. 5 ), BCL-2 ( Fig. 6, 7) n/a apoptosis Tian 2013 23948104 ischemic transient OGD in primary rat BMEC in vitro
Annexin A5/7-AAD ( Fig. 4 ), Hoechst33258/PI ( (Fig. 1, 2, 4) , cleaved caspase-3 ( Fig. 2, 4) , BCL2, BAX (Fig. 2, 5 (Fig. 1, 3) , Golgi fragmentation GRASP65 (Fig. 2) , cleaved caspase-3 ( Fig. 3) , BCL-2 ( Fig. 4, 6) , BCL-XL ( Fig. 6 (Fig. 2) , Hoechst, Annexin A5/PI (Fig. 5) , Bcl-2, Bax, caspase-3 ( Fig. 6) n/a apoptosis Zhang 2017 28347817 ischemic permanent OGD in rat BMEC in vitro Hoechst, MTT (Fig. 1) , TUNEL, BCL-2, BAX (Fig. 3 MTT, cleaved caspase-3 ( Fig. 3, 4 , 6, 7), Annexin A5/PI (Fig. 3 (Fig. 3, 6 ), TUNEL (Fig. 3) , cleaved caspase-3, BAX, BCL-2 ( Fig. 4, 6) ENOPH1 apoptosis Zhang 2018 30419554 ischemic transient OGD in human HBMEC in vitro BAX (Fig. 3, 4) , Annexin A5/PI (Fig. 4) (Fig. 1) , LDH (Fig. 2) , 3-MA (Fig. 2, 3) , Annexin A5/PI (Fig. 3 MTT, Annexin A5/PI, DAPI (Fig.  7) , cleaved caspase-3, mitochondrial membrane potential ( Fig. 8 (Fig. 1, 2, 4) , cleaved caspase-3 (Fig. 2, 4) , BCL-XL, BAX (Fig. 3, 6 MTT, BAX, BCL2, cleaved caspase-3 ( Fig. 1) , mitochondrial fission/DRP1 (Fig. 2) , Rapamycin, chloroquine, 3-methyladenine treatment + MTT, LC3-II (Fig. 3) , Mdivi-1 treatment + MTT, DRP1, LC3-II ( Fig. 4) reactive oxygen species, DRP1, autophagy autophagy Engelhar dt 2015 25879623 ischemic RBE4, primary rat brain EC in OD and OGD in vitro MTT (Fig. 5 ), BNIP3 (Fig. 6) , BAX, Beclin-1 ( Fig. 7) , LC3-II ( Fig. 8) n/a autophagy Fu 2019 30962864 ischemic transient OGD in human BMVEC in vitro CCK-8, Annexin A5/PI, EM to assess autophagy but no criteria mentioned (Fig. 1) , LDH (Fig. 2) , mTOR, Beclin-1, Bcl-2, Bax, LC3-II, cleaved caspase-3 ( Fig. 4) n/a autophagy Garbuzo va-Davis 2014 24610730 ischemic rat transient MCAO in vivo EM examination of microvasculature, formation of autophagosomes, large vacuoles ( Fig. 1, 2) , Beclin-1 (Fig. 4, 5) n/a autophagy Han 2011 21392095 ischemic rat microvessels from permanent microsphere embolism model in vivo in microvessels: Cathepsin B + vWF (Fig. 5 ), Cathepsin B +ZO-1 (Fig. 7) , LC3-II (Fig 5, 6) rapamycin, lithium carbonate, 3methyladenine treatment and LC3-II ( Fig. 1) , Hoechst (Fig. 2 Beclin-1+collagenIV-positive microvessels (Fig. 5) , Beclin-1+ collagenIV+ TUNEL-positive microvessels (Fig. 6) n/a autophagy Li 2017 28433650 ischemic transient OGD in mouse primary BMEC in vitro LC3-II, Trypan Blue, PI (Fig. 1, 4) , 3-methyladenine treatment, lithium carbonate ( Fig. 1) Malat1, miRNA, Unc-51 like autophagy activating kinase 2 autophagy Lonati 2019 31370282 ischemic transient OGD in RBE4 in vitro Beclin-1 (Fig. 6 ), LC3-II (Fig. 6, 7 CCK-8 ( Fig. 1) , Annexin A5/PI, BCL2, cleaved caspase-3, autophagosome (EM), mTOR, Beclin-1 (Fig. 2 Fig. 3 ), in vitro: flow cytometry -marker not mentioned (Fig. 4) , LC3-II, rapamycin treatment (Fig. 6 (Fig.  1) , CD31 (Fig. S1 ), in vitro: CCK-8, shAtg7 (Fig. S3) Atg7, NF-kB autophagy Wang 2019 30496821 ischemic permanent OGD in bEnd.3 in vitro LC3 (Fig. 1, 2, 4, 6) , MTT, LDH (Fig. 2, 4, 6 LDH, MTT (Fig. 2) , LC3-II (Fig.  6A) , in vivo: cell death only in whole tissue n/a autophagy Zhang 2019 30787267 ischemic transient and permanent OGD in rat BMEC in vitro MTT (Fig. 1) , LDH (Fig. 2) , 3-MA (Fig. 2, 3) , Annexin A5/PI (Fig. 3) , AO/MDC (acridine orange/ monodansycadaverine, autophagosomes, Fig. 4 Calpain-1/2 activity (Fig. 2) , pJNK1/2 and cleaved caspase-3 ( Fig. 5 in microvessels: Cathepsin B + vWF (Fig. 5) , Cathepsin B +ZO-1 (Fig. 7) , LC3-II (Fig 5, 6) MTT, LDH (Fig. 2) , Hoechst/PI (Fig. 3) , AnxA5/PI, cleaved caspase-3, RIPK1, RIPK3, Necrostatin-1 (Fig. 4) necroptosis mechanism unspecific Cao 2016 26915982 ischemic permanent OGD in bEnd.3 in vitro MTT (Fig. 2) n/a unspecific Ceruti 2011 21672581 ischemic permanent GD or OGD in rat brain capillary EC in vitro LDH, PI (Fig. 3 phase-contrast (morphology), CCK-8 ( Fig. 4) , only whole brain neuronal death, microvessels transcription factor expression, (Fig. 1) , LDH (Fig. 1, 4 ) sirtuin 6
unspecific Huang 2016 27592408 ischemic transient OGD in prim. rat cortical EC in vitro in vitro: MTT (Fig. 6 ), in vivo: increase in CD31 staining (Fig. 4,  5) n/a unspecific Hwang 2019 31024439 ischemic rat transient MCAO, transient OGD in bEnd.3 both in vivo: CD31 (Fig. 5 ), in vitro: Trypan blue, WST-8 ( Fig. 7 (Fig. 2, 3 in vitro MTT (Fig. 1, 2 (Fig. 1, 5 ) SNHG12, miR199a, VEGF unspecific Lyden 2018 30461327 ischemic transient OGD in primary rat brain EC in vitro MTT, LDH (Fig. 2, 4 Fig. 1, 3, 4 ) n/a unspecific Panickar 2015 24773045 ischemic permanent OGD in bEnd.3 in vitro cell swelling (Fig. 1, 2 ) n/a unspecific Park 2013 23374901 ischemic transient OGD in bEnd.3 in vitro LDH ( Fig. 1-3) methallothionein, signal transducer and activator of transcription 3 unspecific Redzic 2015 24206924 ischemic permanent OGD in primary rat brain EC in vitro LDH (Fig. 3-6 ) n/a unspecific Ren 2018 30038058 ischemic permanent OGD in primary mouse BMEC in vitro MTT (Fig. 1) LncRNA-MALAT, miR-145, VEGF, angiopoietin-2 unspecific Salvador 2015 26347611 ischemic transient OGD in mouse cerebrovascular EC (cEND) in vitro OGD: LDH (Fig. 3) , intracellular Ca 2+ (Fig. 11 in vitro CCK-8, MTT (Fig. 1, 2, 4 (Fig. 2, 4) , PI (Fig. 2 Supplemental Table 3 . Risk of bias assessment of the included studies. The assessment was performed with respect to the endothelial cell death measurements. Green indicates low risk, red indicates high risk, and yellow indicates unclear risk due to lack of information or uncertainty over the potential for bias. Four studies were biased for incomplete outcome analysis due to unexplained unequal numbers of biological replicates. A common statistical issue identified is the use of statistical tests that require normally distributed data (e.g., t-test or ANOVA) without reporting that normal distribution or the homogeneity of variance was tested or confirmed (yellow label). Incorrect statistical tests (red label) were reported when parametric tests were performed with a sample size (n=3-4 per group) insufficient to assume normal distribution or when t-tests were used for multiple comparisons. NA: not applicable. 
11
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
12
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Supplemental data
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
12-13
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). n/a Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I 2 ) for each meta-analysis.
n/a Section/topic # Checklist item Reported on page #
Risk of bias across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
25-26
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
n/a
RESULTS

Study selection
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
12-13
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Supplemental Table 1 Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Supplemental  Table 3 Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
n/a Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. n/a
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15).
25-26
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). n/a DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
13-22
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
25-26
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 26
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
27
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit: www.prisma-statement.org.
